Skip to main content
. 2018 May 17;3(2):295–298. doi: 10.1002/epi4.12224

Table 1.

Patients with mild mutations in at least one disease gene allele and atypical LD course compared to the patient in the present study with gene‐inactivating mutation and typical course

References Sex Mutation type/gene Nucleotide (amino acid change) Age of onset Age at follow‐up Clinical status at time of follow‐up
Present paper F Nonsense/EPM2A c.163C>T (p.Gln55Ter) 13 20 Severe cognitive impairment; severe myoclonus; limited speech; unable to walk or feed
7 M Missense/ EPM2B c.436 G>A (D146N) 19 32 Mild myoclonus; normal cognition
7 M Missense/ EPM2B c.436 G>A (D146N) 21 29 Mild myoclonus; normal cognition
7 M Missense/ EPM2B c.436 G>A (D146N) 17 28 Mild myoclonus; normal cognition
7 M Missense/ EPM2B c.436 G>A (D146N) 21 25 Mild myoclonus; normal cognition
8 M Missense/ EPMzx 2B c.436 G>A (D146N) 30 48 Dementia; no disabling myoclonus
9 F Missense/ EPM2B c.436 G>A (D146N) 19 22 Cognitive impairment; no myoclonus
10 M Missense/ EPM2B c.436 G>A (D146N) 15 29 Mild cognitive impairment; no interference with daily living activities; mild myoclonus
10 M Missense/ EPM2B c.436 G>A (D146N) 18 28 Mild cognitive impairment; no interference with daily living activities
10 M Missense/ EPM2B c.436 G>A (D146N) 13 32 Mild cognitive impairment; no interference with daily living activities; absence seizures
11 F Compound heterozygous/ EPM2A c.721G> T (p.R241X) (nonsense) and c.835G> T (p.G279C) (missense) 21 28 Mild myoclonus; slow progressing ataxia; mild to moderate cognitive decline.
11 F Compound heterozygous/ EPM2A c.721G> T (p.R241X) (nonsense) and c.835G> T (p.G279C) (missense) 25 30 Mild cognitive impairment; no ataxia; some myoclonus and GTCS
11 F Compound heterozygous/ EPM2A c.721G> T (p.R241X) (nonsense) and c.835G> T (p.G279C) (missense) 28 33 No cognitive impairment; no ataxia; myoclonus only
12 F Missense/ EPM2A c.962T>G (p. F321C) Early 20s 53 Slowly progressing bradykinesia; rigidity in limbs; mild cognitive decline